scholarly journals A novel approach to assess pulmonary function in patients with chronic obstructive pulmonary disease using tissue velocity imaging.

2016 ◽  
Vol 18 (2) ◽  
pp. 177
Author(s):  
Xiao-Zhi Zheng ◽  
Jing Wu ◽  
Xu-Yan Tan
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Function ◽  
Strain Rate ◽  
Pulmonary Disease ◽  
Predictive Value ◽  
Lung Ultrasound ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Tissue Velocity ◽  
Velocity Imaging

Aims: To explore the feasibility of quantitative evaluation of pulmonary function in patients with chronic obstructive pulmonary disease (COPD) using tissue velocity imaging (TVI) and strain rate imaging (SRI) via transthoracic lung ultrasonography. Material and methods: Eighty inpatients with clinically diagnosed COPD underwent pulmonary function test and transthoracic lung ultrasound on the same day. Lung ultrasound variables and pulmonary function parameters were analyzed. Results: All patients with COPD had faster breathing and significant reduced lung function compared with healthy participants (p<0.05). The lung ultrasound parameters, velocity (max-min, cm/s), displacement (max-min, mm), strain (max-min, %) and strain rate (max-min, 1/s) were significantly higher in patients with COPD (p<0.05). A good negative correlation was found between lung ultrasound variables and pulmonary function parameters in patients with COPD. Stepwise multiple regression analysis indicated that the velocity (max-min, cm/s) was the only independent determinant of FEV1/FVC (%). With the use of FEV1/FVC<70% as the criteria of irreversible pulmonary function impairment to distinguish an abnormal pulmonary function, the area under the ROC was 0.99 for the velocity (max-min, cm/s) of the lung tissue in the process of breathing. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the cut off value (1.19 cm/s) was 97.63%, 100%, 100%, 80%,  and 98%, respectively (p<0.001). Conclusions: Tissue velocity imaging via transthoracic lung ultrasound is a useful modality in the assessment of pulmonary function in patients with COPD.

SLOWING THE DETERIORATION OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE OBSERVED DURING BRONCHODILATOR THERAPY BY ADDING INHALED CORTICOSTEROIDS: A 4-YEAR PROSPECTIVE STUDY

PEDIATRICS ◽  
1994 ◽  
Vol 94 (2) ◽  
pp. 269-270
Author(s):  
Peter Cvietusa ◽  
Joseph Spahn ◽  
William R. Otto
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Function ◽  
Pulmonary Disease ◽  
Bronchial Hyperreactivity ◽  
Rapid Decline ◽  
Chronic Obstructive ◽  
Exacerbation Rate ◽  
Obstructive Pulmonary Disease ◽  
Bronchodilator Therapy ◽  
Inhaled Steroids

Purpose of the Study. To determine if the deterioration in lung function, seen in adults with asthma or chronic obstructive pulmonary disease (COPD), could be reversed or slowed by the addition of inhaled beclomethasone. Many short-term studies have shown the benefits of inhaled steroids in asthma; in particular, their ability to improve pulmonary function, decrease bronchial hyperreactivity, and reduce symptoms. Few studies have evaluated the long-term effects of inhaled steroids on the clinical course of either asthma or COPD. Methods. This report is an extension of a 2-year study that followed 160 patients with asthma or COPD on bronchodilator therapy alone. From this group, 56 patients who displayed a rapid decline in pulmonary function (FEV1 ≥ 80 ml/year) and a high exacerbation rate (≥1/year) were selected to receive additional treatment with beclomethasone dipropionate 400 µg two times daily over 4 years. FEV1 and airways responsiveness to histamine were measured every 6 months and at 1 and 13 months upon completion of the study. Peak flows and symptom scores were recorded weekly, and compliance, inhaler technique, and adverse affects were monitored every 3 months. Findings. During the first 6 months of beclomethasone treatment, both groups showed a significant improvement in pre- and postbronchodilator FEV1 with the most significant change noted in the asthma group. Thereafter, the FEV1 began to decline again, as it had in the first 2 years of the study, but at a rate that was 33% slower. In addition to slowing the decline in FEV1, inhaled beclomethasone resulted in a substantial decrease in the degree of bronchial hyperreactivity, and peak flow rates improved.

Prediction of chronic obstructive pulmonary disease stages using machine learning algorithms

2022 ◽  
Vol 14 (1) ◽  
pp. 0-0
Keyword(s):  
Machine Learning ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Predictive Value ◽  
Learning Algorithms ◽  
Machine Learning Algorithms ◽  
Chronic Obstructive ◽  
Optimal Prediction ◽  
Obstructive Pulmonary Disease ◽  
Disease Stages

Identifying chronic obstructive pulmonary disease (COPD) severity stages is of great importance to control the related mortality rates and reduce the associated costs. This study aims to build prediction models for COPD stages and, to compare the relative performance of five machine learning algorithms to determine the optimal prediction algorithm. This research is based on data collected from a private hospital in Egypt for the two calendar years 2018 and 2019. Five machine learning algorithms were used for the comparison. The F1 score, specificity, sensitivity, accuracy, positive predictive value and negative predictive value were the performance measures used for algorithms comparison. Analysis included 211 patients’ records. Our results show that the best performing algorithm in most of the disease stages is the PNN with the optimal prediction accuracy and hence it can be considered as a powerful prediction tool used by decision makers in predicting severity stages of COPD.

Sign in / Sign up

Export Citation Format

Share Document